• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Improved Sleep Continuity and Increased Slow Wave Sleep and REM Latency During Ziprasidone Treatment: A Randomized, Controlled, Crossover Trial of 12 Healthy Male Subjects.
【24h】

Improved Sleep Continuity and Increased Slow Wave Sleep and REM Latency During Ziprasidone Treatment: A Randomized, Controlled, Crossover Trial of 12 Healthy Male Subjects.

机译：Ziprasidone治疗期间改善的睡眠连续性和增加的慢波睡眠和REM潜伏期：一项针对12位健康男性受试者的随机，对照，交叉试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Ziprasidone, an atypical antipsychotic, is a potent dopamine (D(2)) and serotonin (5-HT(2A/C)) receptor blocker, has agonistic properties at the 5-HT(1A) receptor, and blocks serotonin and norepinephrine reuptake. These transmitter systems are closely related to the regulation of sleep. METHOD: The aim of this double-blind, placebo-controlled, randomized, crossover study was to investigate the effects of ziprasidone on polysomnographic sleep structure and subjective sleep quality. Twelve healthy male subjects were randomly assigned to receive ziprasidone 40 mg or placebo for 2 sessions each composed of 2 consecutive nights (night 1, standard sleep conditions; night 2, acoustic stress) 5 days apart. Treatment was administered orally 2 hours before bedtime. The study was conducted from April 2004 to July 2004. RESULTS: Ziprasidone significantly increased total sleep time, sleep efficiency, percentage of sleep stage 2, and slow wave sleep; decreased the number of awakenings; and significantly affected tonic and phasic REM sleep parameters, i.e., it decreased percentage of REM and REM density and profoundly increased REM latency. CONCLUSION: Ziprasidone's effects on the sleep profile are somehow opposite to what is known about sleep of depressed patients (e.g., disturbances of sleep continuity, a reduciton of slow wave sleep, and a disinhibition of REM sleep). Its REM sleep-suppressing properties resemble those of most, although not all, antidepressants and may be clinically relevant. The drug also demonstrates sleep-consolidating properties under both standard routine and acoustic stress conditions. These effects are most likely related to ziprasidone's 5-HT(2C) antagonism, 5-HT(1A) agonism, and serotonin and norepinephrine reuptake inhibition.
机译：目的：非典型抗精神病药Ziprasidone是一种强力的多巴胺（D（2））和5-羟色胺（5-HT（2A / C））受体阻滞剂，对5-HT（1A）受体具有激动作用，并阻断5-羟色胺和去甲肾上腺素再摄取。这些发射器系统与睡眠调节密切相关。方法：这项双盲，安慰剂对照，随机，交叉研究的目的是研究齐拉西酮对多导睡眠图睡眠结构和主观睡眠质量的影响。十二名健康男性受试者被随机分配接受40 mg齐拉西酮或安慰剂治疗，每次治疗2次，每次连续2天（晚上1，标准睡眠条件;晚上2，声压），间隔5天。就寝前2小时口服治疗。该研究于2004年4月至2004年7月进行。结果：齐普拉西酮显着增加了总睡眠时间，睡眠效率，第2阶段睡眠的百分比和慢波睡眠。减少唤醒次数;并显着影响补品和阶段性REM睡眠参数，即降低REM的百分比和REM密度并显着增加REM潜伏期。结论：齐普拉西酮对睡眠状况的影响在某种程度上与抑郁症患者的睡眠相反（例如，睡眠连续性障碍，慢波睡眠减少和REM睡眠抑制）。它的REM睡眠抑制特性与大多数（尽管不是全部）抗抑郁药类似，并且可能与临床有关。该药物还显示出在常规常规和声应激条件下的巩固睡眠性能。这些影响最有可能与齐拉西酮的5-HT（2C）拮抗作用，5-HT（1A）激动作用以及5-羟色胺和去甲肾上腺素再摄取抑制有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号